Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$268K Hold
9,380
– – 0.01% 217
2026
Q2
$226K Buy
+9,380
New +$245K 0.01% 231
2017
Q1
– Sell
-564,976
Closed -$17.4M – 195
2016
Q4
$17.4M Sell
564,976
-504,181
-47% -$15.4M 1.49% 22
2016
Q3
$34.4M Sell
1,069,157
-10,540
-1% -$352K 1.22% 12
2016
Q2
$36.1M Buy
1,079,697
+35,204
+3% +$1.12M 1.86% 10
2016
Q1
$29.4M Buy
1,044,493
+17,918
+2% +$512K 2.3% 13
2015
Q4
$31.4M Buy
1,026,575
+8,221
+0.8% +$259K 1.19% 9
2015
Q3
$30.3M Buy
1,018,354
+125,321
+14% +$4.02M 1.86% 7
2015
Q2
$28.4M Buy
893,033
+5,059
+0.6% +$165K 2.15% 9
2015
Q1
$29.3M Buy
887,974
+487,243
+122% +$15.5M 2.33% 7
2014
Q4
$11.8M Buy
400,731
+2,319
+0.6% +$66.5K 0.88% 27
2014
Q3
$11.2M Sell
398,412
-426,870
-52% -$12M 0.59% 25
2014
Q2
$23.2M Buy
825,282
+222,499
+37% +$6.34M 1.44% 17
2014
Q1
$18.4M Buy
602,783
+114,886
+24% +$3.43M 1.59% 15
2013
Q4
$14.2M Buy
+487,897
New +$14.2M 1.03% 20

Other funds holding PFE

Sprott's PFE Position: Q3 2026 in Review

Sprott held its Pfizer (PFE) position steady in Q3 2026 at 9,380 shares worth $268K. The position accounts for 0.01% of the portfolio, ranked #217.

Sprott first reported a position in PFE in Q4 2013 and has held it in 15 quarters since. The position peaked at $36.1M in Q2 2016. 2,556 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Sprott held 9,380 shares of Pfizer worth $268K as of Q3 2026.
  • Sprott left its Pfizer share count unchanged in Q3 2026.
  • Pfizer made up 0.01% of Sprott's portfolio in Q3 2026, its #217 holding.
  • Sprott first reported a position in Pfizer in Q4 2013 and has held it in 15 quarters since.
  • Sprott's Pfizer position peaked at $36.1M in Q2 2016.
  • 2,556 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Sprott's 13F filing for Q3 2026, filed 9 Nov 2026.